Clinical trial shows new drug combo effective in prostate cancer treatment

Mar 1, 2017

Preliminary results from an ongoing clinical trial from former Clinical Fellow Fatima Karzai shows that PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib work together to reduce the prostate-specific antigen (PSA) number. PSA is a protein produced by cells of the prostate gland and is usually elevated in men with prostate cancer. Eight out of 10 patients in this trial experienced reduction in PSA levels with five patients experiencing a 50 percent or more decrease from baseline. Karzai presented this information at the 2017 Genitourinary Cancers Symposium.

Clinical trial shows new drug combo effective in prostate cancer treatment

Genome sequencing of Ewing sarcoma patients reveals genetic predisposition

Feb 23, 2017

The largest and most comprehensive genomic analysis of individuals with Ewing sarcoma performed to date reveals that some patients are genetically predisposed to developing the cancer.  Learn more...

Low-grade prostate tumors can harbor signs of aggressive cancer

Feb 14, 2017

In a new study, Center for Cancer Research investigators found that low-grade and high-grade regions of prostate tumor tissue shared mutations typically linked to aggressive cancer. Testing for mutations to specific genes could help clinicians decide whether a patient with an initial low-grade result should undergo a follow-up biopsy. Learn more...

Novel target for high-risk neuroblastoma identified in pre-clinical research

Jan 9, 2017

Pre-clinical research by investigators at the Center for Cancer Research and their colleagues have identified a number of novel epigenetic targets for high-risk neuroblastoma and validated a promising new targeted inhibitor in pre-clinical models.  Read more...

Molecules discovered that block cancer-associated microRNAs

Dec 29, 2016

Investigators from the Center for Cancer Research have identified a new class of compounds that block the action of a microRNA associated with the development of human cancers, cardiovascular diseases and immune disorders.  Read more...

NF1 protein structure

Brigitte Widemann leads early-phase trial that shows drug shrinks NF1 tumors

Dec 28, 2016

Brigitte Widemann, Chief of the Pediatric Oncology Branch, led an early-phase clinical trial testing the oral drug selumetinib on children with neurofibromatosis 1 (NF1) and plexiform neurofibromas. The trial results, published in the New England Journal of Medicine on Dec. 28, 2016, showed participants of this trial tolerated the drug and most responded with tumor shrinkage. “Some may say that a 20 percent volume reduction is too small to be meaningful, but to me, just stopping the growth of these devastating tumors is an important achievement,” Widemann says. “The difference we see in these patients is truly unprecedented.” Read more...

Brigitte Widemann leads early-phase trial that shows drug shrinks NF1 tumors

Potential treatment for radiation-induced lung injury identified

Dec 22, 2016

Researchers from the Center for Cancer Research’s Radiation Oncology Branch have identified a therapeutic target for the possible treatment of lung injury from radiation therapy. Read more...

A normal cell, and a cell in which contacts between centromeres and the LINC complex have been abolished.

A crucial step in cell division identified

Dec 20, 2016

When cell division doesn’t go according to plan, the resulting daughter cells can become unstable or even cancerous. A team of CCR investigators has now discovered a crucial step required for normal cell division to occur. Read more...

Chemotherapy drug shuts down cell growth by triggering a natural checkpoint

Dec 15, 2016

In a new study published November 23, 2016, in Molecular Cell, researchers in the CCR’s Laboratory of Cell and Developmental Signaling reported the discovery of a previously unknown route for blocking cell growth that can be activated by certain chemotherapy drugs to fight cancer. Read more...

Cellular immunotherapy targets a common human cancer mutation

Dec 8, 2016

A team of researchers led by Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, studied the use of immunotherapy for colorectal cancer. The team identified a method to target the cancer-causing protein produced by a mutant form of the KRAS gene. The patients who participated in the study experienced tumor regression after receiving this targeted immunotherapy approach. The New England Journal of Medicine published the study results on Dec. 8, 2016. Read more...

Cellular immunotherapy targets a common human cancer mutation